Johana Becerra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Johana Becerra has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Nilton Lincopan
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil
5 shared publications - Felipe Vásquez-Ponce
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
4 shared publications - Herrison Fontana
Department of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo, Brazil
3 shared publications - Thais Martins-Gonçalves
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
3 shared publications - Guilherme E. Paiva
Department of Microbiology, Institute of Biomedical Sciences, Universidade de São Paulo, São Paulo, Brazil
2 shared publications - Jesus G. M. Pariona
Department of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo, Brazil
2 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1525
Phylogeographic analysis of Staphylococcus nepalensis reveals global occurrence of antimicrobial-resistant lineages carrying the sal(E) resistance gene
Background: Staphylococcus nepalensis is an emerging species first described in 2003 from the respiratory tract of goats in Nepal. We report the identification of S. nepalensis of a hypersaline lagoon in Brazil, along with in-depth phylogeographical and resistome analysis of publicly available genomes. Methods and results: During a local survey from hypersaline aquatic environments in Rio de Janeiro, Brazil, two staphylococcal strains were recovered, designated as COLB and AM1. These isolates were subjected to antimicrobial susceptibility testing, genomic sequencing, and comprehensive phylogenomic analyses. Genomic analysis confirmed the taxonomic identity of COLB and AM1 as S. nepalensis. Both isolates harbored the sal (E) conferring resistance to pleuromutilins and streptogramin A, whereas tet (K) conferring to tetracyclines. Additionally, AM1 carried lnu (A), consistent with the reduced susceptibility to clindamycin (MIC = 2 µg/mL) relative to COLB. Genes associated with arsenic and copper tolerance, and the replicons rep7a and rep19c , were confirmed. Phylogenomic analysis indicated that COLB and AM1 were clonally related (1 cgSNP-difference) but distinct from global isolates. Phylogeographic analysis revealed wide geographic occurrence, with some lineages carrying blaZ and mecA associated with beta-lactamase production and methicillin resistance, respectively. Strikingly, sal (E) is conserved across all S. nepalensis genomes. Conclusions: The findings confirm the presence of S. nepalensis in South America as early as 2016 and documented among available genomes from environmental, human, and animal-associated sources. Furthermore, reveal the circulation of some lineages carrying clinically relevant antimicrobial genes, underscoring the importance of accurate species identification and continuous genomic surveillance and potential One Health relevance.
- 4 September 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1525
Open AccessPhylogeographic analysis of Staphylococcus nepalensis reveals global occurrence of antimicrobial-resistant lineages carrying the sal(E) resistance gene
Background: Staphylococcus nepalensis is an emerging species first described in 2003 from the respiratory tract of goats in Nepal. We report the identification of S. nepalensis of a hypersaline lagoon in Brazil, along with in-depth phylogeographical and resistome analysis of publicly available genomes. Methods and results: During a local survey from hypersaline aquatic environments in Rio de Janeiro, Brazil, two staphylococcal strains were recovered, designated as COLB and AM1. These isolates were subjected to antimicrobial susceptibility testing, genomic sequencing, and comprehensive phylogenomic analyses. Genomic analysis confirmed the taxonomic identity of COLB and AM1 as S. nepalensis. Both isolates harbored the sal (E) conferring resistance to pleuromutilins and streptogramin A, whereas tet (K) conferring to tetracyclines. Additionally, AM1 carried lnu (A), consistent with the reduced susceptibility to clindamycin (MIC = 2 µg/mL) relative to COLB. Genes associated with arsenic and copper tolerance, and the replicons rep7a and rep19c , were confirmed. Phylogenomic analysis indicated that COLB and AM1 were clonally related (1 cgSNP-difference) but distinct from global isolates. Phylogeographic analysis revealed wide geographic occurrence, with some lineages carrying blaZ and mecA associated with beta-lactamase production and methicillin resistance, respectively. Strikingly, sal (E) is conserved across all S. nepalensis genomes. Conclusions: The findings confirm the presence of S. nepalensis in South America as early as 2016 and documented among available genomes from environmental, human, and animal-associated sources. Furthermore, reveal the circulation of some lineages carrying clinically relevant antimicrobial genes, underscoring the importance of accurate species identification and continuous genomic surveillance and potential One Health relevance.
- Open Access
- 25 August 2026
- Published by Elsevier in New Microbes and New Infections
- Vol. 73
Illegally trafficked exotic snake as a reservoir for the novel carbapenem-resistant and hypervirulent Pseudomonas aeruginosa ST4309
- 25 August 2026
- Published by Elsevier in New Microbes and New Infections
- Vol. 73
Open AccessIllegally trafficked exotic snake as a reservoir for the novel carbapenem-resistant and hypervirulent Pseudomonas aeruginosa ST4309
- Open Access
- 11 November 2025
- Published by Wiley in Microbiologyopen
- Vol. 14 (6) , e70131
Emergence of Livestock‐Associated Methicillin‐Resistant Staphylococcus aureus ST398 in Wild Birds, Brazil
Antimicrobial‐resistant and virulent Staphylococcus aureus strains are spreading across diverse environments and hosts, but studies on Brazilian wildlife remain limited. From April to December 2021, oropharyngeal swabs were collected from 197 wild birds spanning five orders, 25 families, and 54 species in São Camilo State Park, a protected Atlantic Forest fragment facing significant pressure from surrounding agricultural landscapes. S. aureus was detected in 12.2% of the birds, including 27 methicillin‐susceptible S. aureus (MSSA) and two Methicillin‐resistant (MRSA) isolates. MSSA strains showed high inducible Macrolide‐Lincosamide‐Streptogramin B (MLSB) resistance, with 37% carrying the blaZ gene for penicillin resistance, and antimicrobial‐resistant isolates frequently harboring the scn gene. Genomic sequencing identified both MRSA strains as ST398, marking the first report of MRSA ST398 in Brazilian wildlife. These strains displayed a broad resistome, including genes for resistance to multiple antimicrobial classes, as well as a comprehensive virulome, although in vivo assays with Galleria mellonella suggested low virulence. Phylogenomic analysis clustered the MRSA strains with MSSA from swine in northeastern Brazil, suggesting that these strains likely originated in livestock, acquired the SCC mec element, and spread into natural ecosystems. These findings suggest a possible spillover of livestock‐associated antimicrobial‐resistant S. aureus into a protected forest fragment, highlighting the potential for anthropogenic microbial threats to reach wildlife and underscoring the importance of including wild species in antimicrobial resistance surveillance, especially in fragmented ecosystems increasingly exposed to human activities.
- 11 November 2025
- Published by Wiley in Microbiologyopen
- Vol. 14 (6) , e70131
Open AccessEmergence of Livestock‐Associated Methicillin‐Resistant Staphylococcus aureus ST398 in Wild Birds, Brazil
Antimicrobial‐resistant and virulent Staphylococcus aureus strains are spreading across diverse environments and hosts, but studies on Brazilian wildlife remain limited. From April to December 2021, oropharyngeal swabs were collected from 197 wild birds spanning five orders, 25 families, and 54 species in São Camilo State Park, a protected Atlantic Forest fragment facing significant pressure from surrounding agricultural landscapes. S. aureus was detected in 12.2% of the birds, including 27 methicillin‐susceptible S. aureus (MSSA) and two Methicillin‐resistant (MRSA) isolates. MSSA strains showed high inducible Macrolide‐Lincosamide‐Streptogramin B (MLSB) resistance, with 37% carrying the blaZ gene for penicillin resistance, and antimicrobial‐resistant isolates frequently harboring the scn gene. Genomic sequencing identified both MRSA strains as ST398, marking the first report of MRSA ST398 in Brazilian wildlife. These strains displayed a broad resistome, including genes for resistance to multiple antimicrobial classes, as well as a comprehensive virulome, although in vivo assays with Galleria mellonella suggested low virulence. Phylogenomic analysis clustered the MRSA strains with MSSA from swine in northeastern Brazil, suggesting that these strains likely originated in livestock, acquired the SCC mec element, and spread into natural ecosystems. These findings suggest a possible spillover of livestock‐associated antimicrobial‐resistant S. aureus into a protected forest fragment, highlighting the potential for anthropogenic microbial threats to reach wildlife and underscoring the importance of including wild species in antimicrobial resistance surveillance, especially in fragmented ecosystems increasingly exposed to human activities.
- Open Access
- 28 July 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 353-355
Virulent potential of KPC-2-positive Pseudomonas aeruginosa exoS+ belonging to the high-risk clone ST654-O4 identified in Chilean Patagonia
- 28 July 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 353-355
Open AccessVirulent potential of KPC-2-positive Pseudomonas aeruginosa exoS+ belonging to the high-risk clone ST654-O4 identified in Chilean Patagonia
- Open Access
- 5 February 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 6 (4) , 101071
Tracking pandemic pathogens from wastewater surveillance in international airports: Klebsiella pneumoniae ST16 coproducing NDM-4 and OXA-181 arriving in South America
- 5 February 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 6 (4) , 101071
Open AccessTracking pandemic pathogens from wastewater surveillance in international airports: Klebsiella pneumoniae ST16 coproducing NDM-4 and OXA-181 arriving in South America
- 28 October 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 162-168
Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114
Klebsiella pneumoniae producing KPC variants conferring resistance to ceftazidime–avibactam often remain susceptible to meropenem, suggesting a potential therapeutic use of this antibiotic. In this study, the efficacy of clinically relevant concentrations of meropenem was evaluated against high-risk clones of ceftazidime–avibactam-resistant K. pneumoniae strains producing KPC variants, in a tandem in vitro time-kill/in vivo Galleria mellonella survival model. In vitro/in vivo efficacy of meropenem against ceftazidime–avibactam-resistant K. pneumoniae of CG16, CG25 and CG258, producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114 variants, was evaluated using EUCAST dosing recommendation adjusted to the G. mellonella model. For in vivo assays, untreated, meropenem (40 mg/kg × 1)-treated and ceftazidime–avibactam (40 mg/kg ceftazidime–10 mg/kg avibactam × 1)-treated groups were established, with 60 larvae per group. Kaplan–Meier curves, log-rank tests, univariate Cox regression and hazard ratios (HR) were used to assess treatment effects (P < 0.05). For all KPC-variant producers, time-kill assays showed >3 log-kills reduction (−6.91 ± 1.28 SD) after 6 h interaction when exposed to 8–32 mg/L meropenem MIC values (i.e. ≥ × 4 MIC). In the assessment of in vivo efficacy of meropenem, at the 4-day follow-up, mortality rates were 96.7% (untreated), 83.3% (ceftazidime–avibactam-treated) and 13.3% (meropenem-treated) (P < 0.05). Univariate Cox regression analysis showed significantly lower risk in the meropenem group compared to untreated group [HR 0.02 (95% CI: 0.01–0.05)]. These pre-clinical results might support use of meropenem as a potential alternative for treatment of infections due to KPC-variant producers displaying in vitro susceptibility to meropenem.
- 28 October 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 162-168
Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114
Klebsiella pneumoniae producing KPC variants conferring resistance to ceftazidime–avibactam often remain susceptible to meropenem, suggesting a potential therapeutic use of this antibiotic. In this study, the efficacy of clinically relevant concentrations of meropenem was evaluated against high-risk clones of ceftazidime–avibactam-resistant K. pneumoniae strains producing KPC variants, in a tandem in vitro time-kill/in vivo Galleria mellonella survival model. In vitro/in vivo efficacy of meropenem against ceftazidime–avibactam-resistant K. pneumoniae of CG16, CG25 and CG258, producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114 variants, was evaluated using EUCAST dosing recommendation adjusted to the G. mellonella model. For in vivo assays, untreated, meropenem (40 mg/kg × 1)-treated and ceftazidime–avibactam (40 mg/kg ceftazidime–10 mg/kg avibactam × 1)-treated groups were established, with 60 larvae per group. Kaplan–Meier curves, log-rank tests, univariate Cox regression and hazard ratios (HR) were used to assess treatment effects (P < 0.05). For all KPC-variant producers, time-kill assays showed >3 log-kills reduction (−6.91 ± 1.28 SD) after 6 h interaction when exposed to 8–32 mg/L meropenem MIC values (i.e. ≥ × 4 MIC). In the assessment of in vivo efficacy of meropenem, at the 4-day follow-up, mortality rates were 96.7% (untreated), 83.3% (ceftazidime–avibactam-treated) and 13.3% (meropenem-treated) (P < 0.05). Univariate Cox regression analysis showed significantly lower risk in the meropenem group compared to untreated group [HR 0.02 (95% CI: 0.01–0.05)]. These pre-clinical results might support use of meropenem as a potential alternative for treatment of infections due to KPC-variant producers displaying in vitro susceptibility to meropenem.
- Open Access
- 6 May 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 33, 353-359
ACT-107, a novel variant of AmpC β-lactamase from Enterobacter huaxiensis isolated from Neotropical leaf frog (Phyllomedusa distincta) inhabiting the Brazilian Atlantic Forest
- 6 May 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 33, 353-359
Open AccessACT-107, a novel variant of AmpC β-lactamase from Enterobacter huaxiensis isolated from Neotropical leaf frog (Phyllomedusa distincta) inhabiting the Brazilian Atlantic Forest